Dyskinesia clinical trials at University of California Health
2 in progress, 1 open to eligible people
Showing trials for
Transplantation of Human iPS Cell-derived Dopaminergic Progenitors (CT1-DAP001) for Parkinson's Disease (Phase I/II)
open to eligible people ages 40-75
To evaluate the safety and efficacy of transplantation of human induced pluripotent stem cell-derived dopaminergic progenitors, CT1-DAP001, into the corpus striatum in patients with Parkinson's disease
at UCSD
Infusion of Apomorphine: Long-term Safety Study
Sorry, in progress, not accepting new patients
This is a Phase 3, multicenter, open-label, safety and tolerability study of continuous apomorphine infusion in subjects with advanced Parkinson's Disease (PD) whose motor fluctuations remain unsatisfactory with levodopa (or levodopa/carbidopa) and at least one other class of drugs or mode of therapy for PD.
at UCLA
Our lead scientists for Dyskinesia research studies include Joseph Ciacci, MD.